# Instil Bio, Inc.: overview

TIL · Nasdaq · CIK 1789769 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/til.md) · [Financials](/companies/til/financials.md) · [Filings](/companies/til/filings.md) · [Insiders](/companies/til/insiders.md)

Latest reported revenue: [$0](/filings/0001789769-22-000008.md) for Q4 FY2021, three months to 2021-12-31, from the 10-K filed Mar 7, 2022 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001789769-22-000008).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(3.54)](/filings/0001789769-25-000094.md) | not reported | [(4.32)](/filings/0001789769-26-000045.md) | [(3.24)](/filings/0001789769-26-000057.md) | [(2.01)](/filings/0001789769-25-000094.md) | not reported | [(0.62)](/filings/0001789769-26-000045.md) | [(0.63)](/filings/0001789769-26-000057.md) |
| Free cash flow | $m | [(20.1) d](/filings/0001789769-25-000094.md) | [(10.6) d](/filings/0001789769-26-000019.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001789769-22-000008.md) | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(1.48)](/filings/0001789769-23-000035.md) | [(34.46)](/filings/0001789769-24-000036.md) | [(24.00)](/filings/0001789769-25-000017.md) | [(11.39)](/filings/0001789769-26-000019.md) | [(10.70)](/filings/0001789769-26-000019.md) |
| Free cash flow | $m | [(180)](/filings/0001789769-23-000035.md) | [(265)](/filings/0001789769-24-000036.md) | [(103)](/filings/0001789769-25-000017.md) | [(55.7)](/filings/0001789769-26-000019.md) | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/til/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BML Capital Management, LLC](/funds/1616824.md) | 2026-06-30 | $5.0m | 645,600 |  | Unchanged |
| [CPMG Inc](/funds/1372218.md) | 2026-03-31 | $3.4m | 410,922 |  | Not compared |
| [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $2.3m | 292,743 |  | Unchanged |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $1.4m | 177,423 |  | Added +171,045 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.3m | 163,738 |  | Reduced −10,845 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $1.0m | 134,575 |  | Added +1,629 |
| [Kalehua Capital Management LLC](/funds/2106181.md) | 2026-06-30 | $765.9k | 99,600 |  | Reduced −83,430 |
| [Kalehua Capital Management LLC](/funds/2106181.md) | 2026-06-30 | $765.9k | 99,600 |  | Reduced −83,430 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $426.8k | 55,504 |  | Added +3,486 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $386.8k | 50,300 |  | Reduced −8,800 |

## Recent filings

[All 248 filings](/companies/til/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-13 | 17:00 ET | [10-Q](/filings/0001789769-26-000057.md) | Quarterly report, period 2026-06-30 | 0001789769-26-000057 |
| 2026-08-13 | 16:59 ET | [8-K](/filings/0001789769-26-000055.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001789769-26-000055 |
| 2026-06-11 | 16:30 ET | [8-K](/filings/0001789769-26-000048.md) | 5.07 Shareholder vote results | 0001789769-26-000048 |
| 2026-05-15 | 08:31 ET | [10-Q](/filings/0001789769-26-000045.md) | Quarterly report, period 2026-03-31 | 0001789769-26-000045 |
| 2026-05-15 | 08:30 ET | [8-K](/filings/0001789769-26-000044.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001789769-26-000044 |
| 2026-04-24 | 16:20 ET | [DEF 14A](/filings/0001789769-26-000030.md) | Proxy statement, period 2026-06-11 | 0001789769-26-000030 |
| 2026-04-03 | 08:00 ET | [8-K](/filings/0001789769-26-000024.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001789769-26-000024 |
| 2026-03-27 | 07:05 ET | [10-K](/filings/0001789769-26-000019.md) | Annual report, period 2025-12-31 | 0001789769-26-000019 |
| 2026-03-27 | 07:00 ET | [8-K](/filings/0001789769-26-000018.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001789769-26-000018 |
| 2026-01-06 | 17:00 ET | [8-K](/filings/0001789769-26-000004.md) | 1.02 Termination of a material agreement | 0001789769-26-000004 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001789769-26-000019.md), filed Mar 27, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1789769
- Tickers: TIL
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: NY
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.